



Corporate Factsheet

October 2011

The Company

MorphoSys is a leading biotechnology company, which specializes in antibodies. Employing a suite of innovative technologies, the Company is focused on discovering and developing fully human antibodies for human healthcare applications. Our technologies are unique in enabling the optimization of therapeutic antibodies to precisely pre-defined specifications, allowing MorphoSys researchers and their partners to "Engineer the Medicines of Tomorrow". Beyond therapeutics, MorphoSys is also active in the research and diagnostic antibody markets.

Business Strategy

MorphoSys prosecutes its business in three operating segments. The Partnered Discovery segment develops drug candidates for commercial partners. This segment is the foundation of the Company's success and manages partnerships with several renowned biotechnology and pharmaceutical companies involving more than 60 distinct therapeutic development programs. Our strategic alliance with Novartis, one of the largest R&D agreements ever signed between biotech and pharma companies, is one such partnership. The Proprietary Development segment is focused on developing several proprietary therapeutic antibody candidates targeting cancer, inflammation, and infectious diseases. The goal of this segment is to take innovative antibody drugs to clinical proof-of-concept before partnering. MorphoSys's third operating segment, AbD Serotec, delivers high-quality antibodies to the research and diagnostic markets.

Technologies

MorphoSys commands a suite of innovative technologies that is being used to make and optimize the next generation of therapeutic and diagnostic antibody products. These technologies provide rapid and direct access to fully human antibodies. Foremost among our technologies is HuCAL, the Human Combinatorial Antibody Library, a collection of

several billion functional, distinct, fully human antibodies. Importantly, HuCAL comprises features which enable systematic optimization of fully human antibodies – an essential differentiating feature compared to other human antibody generation technologies. The power of HuCAL is apparent in the depth of the pipeline it has been used to create: currently over 70 therapeutic antibody programs. MorphoSys's core technology is protected in the U.S.A., Europe, Japan and Australia by issued patents, with further patent applications pending.



HuCAL PLATINUM® – the latest and most powerful antibody library developed by MorphoSys.

MorphoSys recently took a great technological step forwards by acquiring Sloning BioTechnology, a company developing new methods of synthetic biology. The transaction made MorphoSys the sole source of Sloning's state-of-the-art Slonomics technology, which dramatically improves the assembly and quality of protein libraries. This technology will be used to accelerate the generation of both therapeutic and diagnostic antibodies.

Partnering Activities

A key element of the MorphoSys strategy is to apply its technologies in partnership with pharmaceutical and biotechnology companies. MorphoSys is committed to building on its successful track record in the industry and seeks partnerships with other organizations having complementary interests, research, technologies and expertise. We are particularly interested in organizations with novel antibody-druggable targets and/or early stage therapeutic antibody programs. MorphoSys is open to different partnering structures, from pure licensing through co-development arrangements.

MorphoSys AG

Stock Exchange: Prime Standard, Frankfurt, Germany

Index: TecDAX 30

Security Code Number: MOR/663200

ISIN: DE 0006632003

U.S. Security Code: (Cusip) 617760103 (MPSYY)

No. of Shares Issued (Sep 30, 2011): 23,047,541

Share Price (Sep 30, 2011): EUR 19.23 (XETRA)

No. of Employees Corporate Group (Sep 30, 2011): 457

Revenues 2010 (IFRS): EUR 87.0 million

Net Income 2010 (IFRS): EUR 9.2 million

Diluted Net Profit per Share 2010 (IFRS): EUR 0.40

Morphosys

Engineering the Medicines of Tomorrow

Product Pipeline

1. Partnered Product Pipeline

MorphoSys's partnered product pipeline comprises over 60 antibody programs covering a range of indications, and is being built within several successful partnerships. Of this number, 16 development programs are presently in human clinical trials, with around 20 in preclinical evaluation. All are fully human antibodies made using HuCAL.

Each program is fully financed by the respective partner. MorphoSys profits from successful development in the form of milestone payments and stands to earn royalties on product sales.

2. Proprietary Product Pipeline

MorphoSys has developed proprietary therapeutic antibody candidates in the areas of inflammation and oncology. These drugs will be partnered following clinical proof of concept. Beyond these activities, we are intensifying our internal drug development efforts by adding new programs.

The Company's proprietary antibody pipeline currently comprises the following clinical-stage programs:

MOR103

MOR103 is a HuCAL antibody directed against GM-CSF, a therapeutic target for the treatment of inflammatory diseases that has great potential in a number of indications where current treatments are inadequate. MOR103 is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.

MOR202

MOR202 is a HuCAL antibody directed against CD38, a promising therapeutic target for the treatment of multiple myeloma and certain leukemias. In pre-clinical studies, MOR202 effectively killed cancer cells from primary patient tumor material and showed very effective inhibition of tumor growth in a SCID-mouse tumor model. MOR202 is currently being tested in a Phase I/IIa trial in multiple myeloma patients.

MOR208

MOR208 is a humanized monoclonal antibody in-licensed from Xencor that targets the antigen CD19, and is being developed for the treatment of B cell malignancies and

autoimmune diseases. The antibody incorporates an optimized Fc portion which enhances the elimination of target cells. The program is currently in phase 1 clinical development.

AbD Serotec

The research and diagnostics segment of MorphoSys operates under the brand name AbD Serotec. It serves the research and diagnostic markets, focusing on four inter-related areas. First, our comprehensive catalogue offers products for immediate purchase online. Second, new antibodies are made to order using HuCAL, which allows novel antibodies to be generated within 8 weeks. This is significantly faster than the current market standard, and offers a range of advantages over the use of animals for antibody production. Third, the contract manufacturing unit produces antibodies in larger quantities on behalf of diagnostic customers. And finally, the custom services facility aids customers with specific antibody development challenges. AbD Serotec currently has relationships with more than twenty diagnostic companies and its antibodies are trusted by many thousands of researchers.

Commercial Partners

The Company has partnered with several pharmaceutical and biotechnology companies including (in alphabetic order):

- | | |
|-------------------------|---------------------------|
| – Absynth | – GeneFrontier |
| – Astellas | – Immunogen |
| – Bayer Schering Pharma | – Merck & Co. |
| – Boehringer Ingelheim | – Novartis |
| – Centocor (J&J) | – Oncomed Pharmaceuticals |
| – ContraFect | – Pfizer |
| – Daiichi Sankyo | – Prochon Biotech |
| – F. Hoffmann-La Roche | – Shionogi |
| – Galapagos | – Xencor |

In addition, the Company has various licenses in place that establish freedom to operate for its technologies and offerings.

Management

Management Board

Dr. Simon E. Moroney, *Chief Executive Officer*

Jens Holstein, *Chief Financial Officer*

Dr. Arndt Schottelius, *Chief Development Officer*

Dr. Marlies Sproll, *Chief Scientific Officer*

Contact

Investors:

Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & IR
investors@morphosys.com

Commercial:

Therapeutic Antibodies Unit
bd@morphosys.com

AbD Serotec:

antibodies.muc@ab-direct.com
www.ab-direct.com

MorphoSys AG

Lena-Christ-Str. 48
82152 Martinsried/Planegg
Germany

Tel.: +49 (0) 89 899 27-0
Fax: +49 (0) 89 899 27-222

Email: info@morphosys.com
Website: www.morphosys.com